Fulgent Genetics closes $56.9M Bako and StrataDx acquisition. What it means for anatomic pathology growth, margin risk, and diagnostic consolidation in 2026.
Zai Lab presents new oncology data at AACR 2026. Discover what its ADC and immunotherapy pipeline could mean for future cancer treatment strategies.
Can STK-012 overcome immunotherapy resistance in lung cancer? Explore AACR 2026 data and what it means for IL-2 precision therapies.
Samsung Bioepis and Sandoz expand their biosimilar partnership to cover vedolizumab SB36 and four early-stage candidates. What this means for the IBD biologics market.
Avacta opens Phase 1 trial of FAP-Exd (AVA6103) in four advanced solid tumors. Analysis of what the sustained-release exatecan conjugate must prove in 2026.
Guardant Health partners with Manulife to launch its Shield MCD blood test in Hong Kong, Singapore and the Philippines. Analysis of what this means for oncology.
Sarepta’s ELEVIDYS Cohort 8 targets non-ambulatory Duchenne patients with a sirolimus regimen. What the trial design reveals about the path to label restoration.
Johnson & Johnson launches VARIPULSE pulsed field ablation technology in Peru. Discover what this means for atrial fibrillation treatment and electrophysiology innovation.
Convatec and Eakin Healthcare launch the eakin freeseal ostomy seal in the U.S. Discover what this means for leakage prevention and the evolving ostomy care market.
Aptar’s nasal drug delivery system enters Phase II trial for LTR Pharma’s SPONTAN erectile dysfunction therapy. Discover what this means for intranasal medicines.